Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to temozolomide-based therapy for children with refractory or relapsed neuroblastoma
ISRCTN40708286Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2 trial of bevacizumab, temozolomide, irinotecan, topotecan, Dinutuximab beta and 1 more, sponsored by University of Birmingham. Started Apr 2013; status: completed.
02
Drugs
bevacizumabtemozolomideirinotecantopotecanDinutuximab beta
Beyond the preview
Go deeper on ISRCTN40708286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40708286.